A number of firms have modified their ratings and price targets on shares of Johnson & Johnson (NYSE: JNJ) recently:

  • 1/12/2018 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $160.00 price target on the stock, up previously from $155.00.
  • 1/11/2018 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $150.89 price target on the stock.
  • 1/9/2018 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Royal Bank of Canada.
  • 1/8/2018 – Johnson & Johnson was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $147.40 price target on the stock.
  • 1/2/2018 – Johnson & Johnson was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.
  • 1/1/2018 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $147.40 price target on the stock.
  • 12/22/2017 – Johnson & Johnson was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $146.35 price target on the stock.
  • 12/20/2017 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $147.14 price target on the stock.
  • 12/12/2017 – Johnson & Johnson had its price target raised by analysts at BMO Capital Markets to $161.00. They now have an “outperform” rating on the stock.
  • 12/12/2017 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Sales in J&J’s domestic Pharma segment decelerated in the first half of 2017 as a number of key growth drivers like Remicade and Concerta are facing competition.  However, sales growth accelerated in Q3 and the positive trend is expected to continue in Q4. We believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions – mainly Actelion – can support top-line growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. J&J’s shares have outperformed the industry this year so far.  However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern.”

Shares of Johnson & Johnson (JNJ) traded up $1.31 during midday trading on Tuesday, hitting $147.07. The stock had a trading volume of 5,268,490 shares, compared to its average volume of 6,020,711. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $146.42. The stock has a market capitalization of $394,760.00, a P/E ratio of 25.53, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the business posted $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. research analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.28%. Johnson & Johnson’s payout ratio is 58.33%.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.